Oragenics Inc OGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OGEN is a good fit for your portfolio.
News
-
Oragenics Issues Update to Shareholders
-
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
-
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
-
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
Trading Information
- Previous Close Price
- $4.91
- Day Range
- $4.61–4.64
- 52-Week Range
- $2.60–12.00
- Bid/Ask
- $4.65 / $4.91
- Market Cap
- $11.91 Mil
- Volume/Avg
- 1,568 / 17,223
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 80.45
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease (“COVID-19”) from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.oragenics.com
Valuation
|
Metric
|
OGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.57 |
Price/Sales | 80.45 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OGEN
|
|---|---|
Quick Ratio | 4.14 |
Current Ratio | 5.57 |
Interest Coverage | −428.60 |
Quick Ratio
OGEN
Profitability
|
Metric
|
OGEN
|
|---|---|
Return on Assets (Normalized) | −83.35% |
Return on Equity (Normalized) | −114.64% |
Return on Invested Capital (Normalized) | −93.72% |
Return on Assets
OGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Trzc | $431.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xflprm | $91.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mlccj | $90.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Ntdjx | $41.3 Bil | |
MRNA
| Moderna Inc | Ctwhd | $30.6 Bil | |
ARGX
| argenx SE ADR | Rrjz | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Ptb | $24.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zkqyqy | $21.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xzyyfc | $17.5 Bil | |
INCY
| Incyte Corp | Zdxzst | $12.3 Bil |